Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death

Transplant Immunology

Volumn 28, Issue 4, 2013, Pages 148-153

  Fidler, Samantha J ^a   Irish, Ashley B ^a,b   Lim, Wai ^a   Ferrari, Paolo ^a   Witt, Campbell S ^a,b   Christiansen, Frank T ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Chronic rejection; Donor specific antibody (DSA); Kidney transplant

Indexed keywords

CLASS I DONOR SPECIFIC ANTIBODY; CLASS II DONOR SPECIFIC ANTIBODY; CORTICOSTEROID; CYCLOSPORIN; DONOR SPECIFIC ANTIBODY; HLA ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; UNCLASSIFIED DRUG; ANTIBODY; HLA ANTIGEN CLASS 1;

ADULT; ANTIBODY DETECTION; ANTIBODY MEDIATED REJECTION; ANTIBODY SPECIFICITY; ARTICLE; CAUSE OF DEATH; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; IMMUNOASSAY; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENAL GRAFT DYSFUNCTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; GRAFT REJECTION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; KIDNEY TRANSPLANTATION; MIDDLE AGED; MORTALITY; TREATMENT OUTCOME;

ANTIBODIES; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY TESTING; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84879840972     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2013.05.001     Document Type: Article

References (26)

1. Ekberg H., Tedesco-Silva H., Demirbas A., Vitko S., Nashan B., Gurkan A., et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007, 357:2562-2575.
2. Lamb K.E., Lodhi S., Meier-Kriesche H.U. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011, 11:450-462.
3. Terasaki P., Mizutani K. Antibody mediated rejection: update 2006. Clin J Am Soc Nephrol 2006, 1:400-403.
4. Langan L.L., D'Orsogna L., Park L.P., Hughes T.L., Irish A., Luxton G., et al. HLA antibodies and soluble CD30 are associated with poor renal graft outcome: updated results of a single-center cross-sectional study. Clin Transpl 2006, 219-225.
5. Kaposztas Z., Podder H., Mauiyyedi S., Illoh O., Kerman R., Reyes M., et al. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant 2009, 23:63-73.
6. Einecke G., Sis B., Reeve J., Mengel M., Campbell P.M., Hidalgo L.G., et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009, 9:2520-2531.
7. Terasaki P.I., Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004, 4:438-443.
8. Cooper J.E., Gralla J., Cagle L., Goldberg R., Chan L., Wiseman A.C. Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation 2011, 91:1103-1109.
9. Gebel H.M., Bray R.A., Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant 2003, 3:1488-1500.
10. Bachler K., Amico P., Honger G., Bielmann D., Hopfer H., Mihatsch M.J., et al. Efficacy of induction therapy with ATG and intravenous immunoglobulins in patients with low-level donor-specific HLA-antibodies. Am J Transplant 2010, 10:1254-1262.
11. Bentall A., Cornell L.D., Gloor J.M., Park W.D., Gandhi M.J., Winters J.L., et al. Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant 2013, 13:76-85.
12. Eng H.S., Bennett G., Tsiopelas E., Lake M., Humphreys I., Chang S.H., et al. Anti-HLA donor-specific antibodies detected in positive B-cell crossmatches by Luminex predict late graft loss. Am J Transplant 2008, 8:2335-2342.
13. Honger G., Hopfer H., Arnold M.L., Spriewald B.M., Schaub S., Amico P. Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection. Transplantation 2011, 92:41-47.
14. Otten H.G., Verhaar M.C., Borst H.P., Hene R.J., van Zuilen A.D. Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant 2012, 12:1618-1623.
15. Lefaucheur C., Suberbielle-Boissel C., Hill G.S., Nochy D., Andrade J., Antoine C., et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008, 8:324-331.
16. Sayer D., Whidborne R., Brestovac B., Trimboli F., Witt C., Christiansen F. HLA-DRB1 DNA sequencing based typing: an approach suitable for high throughput typing including unrelated bone marrow registry donors. Tissue Antigens 2001, 57:46-54.
17. Racusen L.C., Halloran P.F., Solez K. Banff 2003 meeting report: new diagnostic insights and standards. Am J Transplant 2004, 4:1562-1566.
18. Susal C., Ovens J., Mahmoud K., Dohler B., Scherer S., Ruhenstroth A., et al. No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a Collaborative Transplant Study report. Transplantation 2011, 91:883-887.
19. Rodriguez L.M., Paris S.C., Arbelaez M., Cotes J.M., Susal C., Torres Y., et al. Kidney graft recipients with pretransplantation HLA CLASS I antibodies and high soluble CD30 are at high risk for graft loss. Hum Immunol 2007, 68:652-660.
20. Susal C., Opelz G. Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation 2002, 73:1269-1273.
21. Susal C., Opelz G. Good kidney transplant outcome in recipients with presensitization against HLA class II but not HLA class I. Hum Immunol 2004, 65:810-816.
22. Song E.Y., Lee Y.J., Hyun J., Kim Y.S., Ahn C., Ha J., et al. Clinical relevance of pretransplant HLA class II donor-specific antibodies in renal transplantation patients with negative T-cell cytotoxicity crossmatches. Ann Lab Med 2012, 32:139-144.
23. Lefaucheur C., Loupy A., Hill G.S., Andrade J., Nochy D., Antoine C., et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010, 21:1398-1406.
24. Hohage H., Kleyer U., Bruckner D., August C., Zidek W., Spieker C. Influence of proteinuria on long-term transplant survival in kidney transplant recipients. Nephron 1997, 75:160-165.
25. Amer H., Fidler M.E., Myslak M., Morales P., Kremers W.K., Larson T.S., et al. Proteinuria after kidney transplantation, relationship to allograft histology and survival. Am J Transplant 2007, 7:2748-2756.
26. Cherukuri A., Welberry-Smith M.P., Tattersall J.E., Ahmad N., Newstead C.G., Lewington A.J., et al. The clinical significance of early proteinuria after renal transplantation. Transplantation 2010, 89:200-207.